RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Ultragenyx Pharmaceutical Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$15.07+0.53 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Ultragenyx Pharmaceutical Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $397.68M | $366.68M | $369.00M | $338.45M | $320.71M | $313.51M | $285.00M | $264.79M | $229.89M | $198.26M | $180.00M | $157.67M | 55.4% | +24.0% |
| Royalty revenue | $319.54M | $303.54M | $304.00M | $292.13M | $289.44M | $276.66M | $275.00M | $257.89M | $251.35M | $224.46M | $183.00M | $112.97M | 44.6% | +10.4% |
| Collaboration and license | – | – | – | – | – | – | $0 | $0 | $0 | $19.80M | $71.00M | $139.57M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $396.28M | $378.28M | $377.00M | $361.05M | $354.43M | $340.32M | $340.00M | $316.25M | $307.15M | $297.55M | $307.00M | $299.06M | 55.3% | +11.8% |
| Latin America | $175.15M | $157.15M | $170.00M | $150.21M | $144.89M | $150.82M | $131.00M | $130.06M | $109.24M | $89.38M | $77.00M | $67.36M | 24.4% | +20.9% |
| Europe, Middle East, and Africa | $124.27M | $116.27M | $108.00M | $103.53M | $97.87M | $87.03M | $80.00M | $70.00M | $60.79M | $54.59M | $48.00M | – | 17.3% | +27.0% |
| Asia-Pacific | $21.52M | $18.52M | $18.00M | $15.79M | $12.95M | $12.00M | $9.00M | $6.18M | $3.87M | $822.00K | $2.00M | – | 3.0% | +66.2% |
| Europe | – | – | – | – | – | – | – | – | – | $54.12M | $47.53M | $42.61M | – | – |
| Japan | – | – | – | – | – | – | – | – | – | $1.05M | $2.22M | $1.18M | – | – |
From the segment and revenue-disaggregation notes of Ultragenyx Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.